Please login to the form below

Not currently logged in
Email:
Password:

cardiovascular drug

This page shows the latest cardiovascular drug news and features for those working in and with pharma, biotech and healthcare.

Lilly trumpets Trulicity heart data in face-off with Novo Nordisk

Lilly trumpets Trulicity heart data in face-off with Novo Nordisk

Eli Lilly has cardiovascular outcome data for its diabetes drug Trulicity that could help it fend off a challenge from Novo Nordisk’s Ozempic. ... GLP-1 drug Victoza (liraglutide), and if it can get a cardiovascular outcomes claim on its label it will

Latest news

More from news
Approximately 2 fully matching, plus 90 partially matching documents found.

Latest Intelligence

  • Perfecting the pharmaceutical pipeline with AI Perfecting the pharmaceutical pipeline with AI

    For example, a drug being used for cardiovascular disease might be found to have useful qualities for neurological diseases. ... We’re already seeing evidence of how AI can positively impact drug discovery.

  • Going the distance Going the distance

    Looking to the second half of this year and Sanofi is aiming for a Q3 launch for its new PCSK9 cardiovascular disease management drug Praluent (alirocumab), which comes from its collaboration ... centric means that you need to think about your patients

  • Interview: Peter Meeus, Novo Nordisk Interview: Peter Meeus, Novo Nordisk

    Several obstacles stand in the way of the uptake of Tresiba in Europe, including the decision from the US FDA to request more data from Novo Nordisk regarding the drug's ... cardiovascular safety before it can be approved.

  • Pharma deals during October 2012 Pharma deals during October 2012

    In return for granting Merck a global exclusive licence to its cardiovascular drug candidates, Theravance will receive $153m in R&D funding and milestone payments, including a $5m upfront payment and ... 101. Advinus / Takeda. 3 yr discovery,

  • Pharma deals during July 2012 Pharma deals during July 2012

    These are Benlysta (belimumab), an antibody approved for the treatment of lupus; darapladib, a phase III small molecule drug for the treatment of cardiovascular disease; and albiglutide, an albumin-fusion protein ... 168. Vestiq / BioAlliance (a). Licence

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • Sanifit appoints Alexander Gold chief medical officer Sanifit appoints Alexander Gold chief medical officer

    Alex arrives here with first class operational and clinical development expertise in novel drug therapies, targeting cardiovascular and metabolic disease and kidney disease amongst others. ... A cardiologist with over 16 years experience of drug

  • Senior AstraZeneca exec jumps ship to small biotech Senior AstraZeneca exec jumps ship to small biotech

    AstraZeneca's chief executive, Pascal Soriot, will take over the job of late-stage drug development on an interim basis, according to news reports. ... Meanwhile Elisabeth Björk, an associate professor of medicine at Uppsala university and leads

  • Milestone names chief medical officer Milestone names chief medical officer

    Cardiovascular specialist Milestone Pharmaceuticals has appointed experienced pharma researcher Dr Francis Plat as its new chief medical officer. ... Milestone's CEO Philippe Douville said: "Dr Plat is the perfect candidate for our development program

  • Jonathan Fox leaves AstraZeneca for MyoKardia Jonathan Fox leaves AstraZeneca for MyoKardia

    He also served for four years as the industry representative to the FDA's Cardiovascular and renal Drug Products Advisory Committee. ... By translating the groundbreaking science of the founding investigators into effective, disease modifying treatments,

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Sildenafil Drug Market Forecast By End-use Industry 2016-2026

    Sildenafil is most common type of drug which is prescribed for erectile dysfunction come under phosphodiesterase type 5 inhibitors (PDE 5).The drug was previously used for some cardiovascular disease and ... The availability of drug in different dosage

  • Packer Forbes News November 2015

    A graduate from the University of Bath, Lydia’ s study areas included Cardiovascular Pharmacology, Regenerative Medicine, Drug Targets in the Immune System with her dissertation focusing on the possibility of a

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics